The rise of GLP-1 receptor agonists such as semaglutide has thinned the waistlines of millions and opened the door for innovation in the US$200 billion supplement and nutraceutical industry. As the accessibility of drugs like Ozempic and Wegovy increases, users are eating less and discovering the biological effects of rapid weight loss.
